{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:42:59Z","timestamp":1783035779153,"version":"3.54.6"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DA053989"],"award-info":[{"award-number":["K23DA053989"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Long-acting injectable (LAI) forms of preexposure prophylaxis and antiretroviral therapy and extended-release medications for opioid use disorder (OUD) may reduce HIV and OUD treatment attrition, but community interest among people who inject drugs remains underexplored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From September to December 2023, we conducted a cross-sectional survey of adults with OUD and a history of injection drug use who were attending a New Jersey syringe exchange program to assess their experiences with HIV and OUD care and their knowledge, attitudes, and preferences about LAI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 193 participants, 15 were persons with HIV (PWH), 72 were high risk for HIV (HRH), and 91 were low risk for HIV (LRH). Many participants had previously taken medications for OUD (60%), but knowledge of extended-release medications for OUD was low (40% PWH, 45.8% HRH, 41.6% LRH, P = .85). Participant interest in extended-release naltrexone (33.3% PWH, 27.8% HRH, 26.7% LRH, P = .91) and extended-release buprenorphine (33.3% PWH, 18.3% HRH, 20.9% LRH, P = .45) was also low. Preexposure prophylaxis knowledge was high (59.1% HRH, 63.9% LRH, P = .54), but prior usage (11.1% HRH, 6.7% LRH, P = .32) and interest (18.1% HRH, 21.1% LRH P = .63) in LAI preexposure prophylaxis were low. PWH had high awareness (66.7%) and interest (66.7%) in receiving LAI antiretroviral therapy. Interest in integrated care was greater for PWH (69.2%) than for those at HRH (29.8%) or LRH (33.9%; P = .03), and preferred treatment locations varied among the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Targeted education and outreach are particularly needed for extended-release medications for OUD and LAI preexposure prophylaxis. A differentiated care model may better address the needs of people who inject drugs with OUD, whether at risk for or with HIV. Addressing barriers to LAI treatment remains essential.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf120","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:54:18Z","timestamp":1741290858000},"source":"Crossref","is-referenced-by-count":1,"title":["Perceptions of People Who Inject Drugs About Long-acting Medications for Opioid Use Disorder, Preexposure Prophylaxis, and Antiretroviral Therapy"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8605-8248","authenticated-orcid":false,"given":"Parisa","family":"Thepmankorn","sequence":"first","affiliation":[{"name":"Department of Medicine, Rutgers New Jersey Medical School , Newark, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Flumo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Rutgers New Jersey Medical School , Newark, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1703-0500","authenticated-orcid":false,"given":"Amesika N","family":"Nyaku","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School , Newark, New Jersey ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025032118062008100_ofaf120-B1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"key":"2025032118062008100_ofaf120-B2","article-title":"Fast facts: HIV in the United States","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2025032118062008100_ofaf120-B3","article-title":"Understanding the current HIV epidemic in the United States","author":"AidsVu","year":"2024"},{"key":"2025032118062008100_ofaf120-B4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2025032118062008100_ofaf120-B5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025032118062008100_ofaf120-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-019-00436-7","article-title":"Medications for treatment of opioid use disorder among persons living with HIV","volume":"16","author":"Fanucchi","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025032118062008100_ofaf120-B7","doi-asserted-by":"crossref","first-page":"ofab289","DOI":"10.1093\/ofid\/ofab289","article-title":"A systematic review and meta-analysis of studies evaluating the effect of medication treatment for opioid use disorder on infectious disease outcomes","volume":"8","author":"McNamara","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025032118062008100_ofaf120-B8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"key":"2025032118062008100_ofaf120-B9","doi-asserted-by":"crossref","first-page":"108506","DOI":"10.1016\/j.jsat.2021.108506","article-title":"Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder","volume":"132","author":"Beck","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2025032118062008100_ofaf120-B10","doi-asserted-by":"crossref","first-page":"e2221346","DOI":"10.1001\/jamanetworkopen.2022.21346","article-title":"Prevalence of HIV preexposure prophylaxis prescribing among persons with commercial insurance and likely injection drug use","volume":"5","author":"Streed","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025032118062008100_ofaf120-B11","doi-asserted-by":"crossref","first-page":"ofac057","DOI":"10.1093\/ofid\/ofac057","article-title":"Access to medications for opioid use disorder for persons with human immunodeficiency virus in the United States: gaps in coverage by state AIDS drug assistance programs","volume":"9","author":"McManus","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025032118062008100_ofaf120-B12","volume-title":"Status neutral HIV prevention and care","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2025032118062008100_ofaf120-B13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2025032118062008100_ofaf120-B14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1007\/s10461-021-03488-2","article-title":"PrEP care continuum engagement among persons who inject drugs: rural and urban differences in stigma and social infrastructure","volume":"26","author":"Walters","year":"2022","journal-title":"AIDS Behav"},{"key":"2025032118062008100_ofaf120-B15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","article-title":"A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs","volume":"31","author":"Biello","year":"2019","journal-title":"AIDS Care"},{"key":"2025032118062008100_ofaf120-B16"},{"key":"2025032118062008100_ofaf120-B17","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5-TR","author":"American Psychiatric Association","year":"2022","edition":"5th ed"},{"issue":"suppl 2","key":"2025032118062008100_ofaf120-B18","first-page":"S281","article-title":"Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors","volume":"10","author":"Navaline","year":"1994","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025032118062008100_ofaf120-B19","doi-asserted-by":"crossref","first-page":"2325958220981265","DOI":"10.1177\/2325958220981265","article-title":"Perceptions of long-acting injectable antiretroviral treatment regimens in a United States urban academic medical center","volume":"19","author":"Koren","year":"2020","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025032118062008100_ofaf120-B20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025032118062008100_ofaf120-B21","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025032118062008100_ofaf120-B22","volume-title":"Fundamental research statistics for the behavioral sciences","author":"Roscoe","year":"1975","edition":"2nd ed"},{"key":"2025032118062008100_ofaf120-B23","volume-title":"The survey research handbook","author":"Alreck","year":"1985"},{"key":"2025032118062008100_ofaf120-B24","volume-title":"Encyclopedia of drugs, alcohol and addictive behavior","author":"Metzger","year":"2001"},{"key":"2025032118062008100_ofaf120-B25","volume-title":"HIV Risk Assessment Battery (RAB)","author":"University of Pennsylvania","year":"2025"},{"key":"2025032118062008100_ofaf120-B26","doi-asserted-by":"crossref","first-page":"e26107","DOI":"10.1002\/jia2.26107","article-title":"Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition","volume":"26","author":"Lorenzetti","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2025032118062008100_ofaf120-B27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.drugalcdep.2018.08.014","article-title":"PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland","volume":"195","author":"Sherman","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2025032118062008100_ofaf120-B28","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1007\/s10461-021-03220-0","article-title":"HIV pre-exposure prophylaxis and buprenorphine at a drug detoxification center during the opioid epidemic: opportunities and challenges","volume":"25","author":"Assoumou","year":"2021","journal-title":"AIDS Behav"},{"key":"2025032118062008100_ofaf120-B29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s10461-017-1851-1","article-title":"Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users","volume":"22","author":"Shrestha","year":"2018","journal-title":"AIDS Behav"},{"key":"2025032118062008100_ofaf120-B30","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10461-016-1612-6","article-title":"Primary care physicians' willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs","volume":"21","author":"Edelman","year":"2017","journal-title":"AIDS Behav"},{"key":"2025032118062008100_ofaf120-B31","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.amepre.2017.01.025","article-title":"Factors related to pre-exposure prophylaxis prescription by US primary care physicians","volume":"52","author":"Walsh","year":"2017","journal-title":"Am J Prev Med"},{"key":"2025032118062008100_ofaf120-B32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","article-title":"Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection","volume":"33","author":"Dandachi","year":"2021","journal-title":"AIDS Care"},{"key":"2025032118062008100_ofaf120-B33","first-page":"164\u2013","article-title":"Interest in and preference for long-acting injectable antiretroviral therapy in the era of approved cabotegravir\/rilpivirine among reproductive-aged women in the US South","author":"Collins","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025032118062008100_ofaf120-B34","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine"},{"key":"2025032118062008100_ofaf120-B35","doi-asserted-by":"crossref","first-page":"108183","DOI":"10.1016\/j.jsat.2020.108183","article-title":"Patients\u2019 perspectives on initiating treatment with extended-release naltrexone (XR-NTX)","volume":"122","author":"Gauthier","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2025032118062008100_ofaf120-B36","doi-asserted-by":"crossref","first-page":"21585","DOI":"10.7448\/IAS.20.1.21585","article-title":"Integrating HIV and substance use services: a systematic review","volume":"20","author":"Haldane","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"2025032118062008100_ofaf120-B37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/09540121.2017.1300634","article-title":"Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences","volume":"29","author":"Guise","year":"2017","journal-title":"AIDS Care"},{"key":"2025032118062008100_ofaf120-B38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11904-023-00667-9","article-title":"Integrated care models: HIV and substance use","volume":"20","author":"Hill","year":"2023","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025032118062008100_ofaf120-B39","doi-asserted-by":"crossref","first-page":"21484","DOI":"10.7448\/IAS.19.1.21484","article-title":"Reimagining HIV service delivery: the role of differentiated care from prevention to suppression","volume":"19","author":"Grimsrud","year":"2016","journal-title":"J Int AIDS Soc"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf120\/62307571\/ofaf120.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf120\/62307571\/ofaf120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf120\/62307571\/ofaf120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:30:12Z","timestamp":1742718612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf120\/8058632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf120","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,28]]},"article-number":"ofaf120"}}